Limited Versus Extended Trophic Feeding (LET-FEED) Trial
NCT06893939 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350
Last updated 2025-07-28
Summary
Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes.
Study Design Type This is a multi-center, open-label, parallel-group, individual randomized controlled trial comparing two different trophic feeding regimens in preterm infants born between 25w0d and 31w6d. These infants will be randomly assigned to either the intervention group, receiving limited trophic feeding (20 to 25 mL/kg/day for one day) or the control group, receiving extended trophic feeding (20 to 25 mL/kg/day for three days) prior to advancing enteral feeds until full feeding volume (140 mL/kg/day) is achieved.
Eligibility Criteria Preterm infants with gestational ages between 25 0/7 and 31 6/7 weeks and a birthweight of \<1500 grams who are admitted to six participating neonatal units will be eligible for inclusion. Infants with \<5th percentile for weight at birth, vasopressor use within first 24 hours of life major congenital/genetic anomalies affecting enteral feeding, growth, or mortality, and those with a terminal illness in which decisions to withhold or limit support have been made will be excluded. Infants of parents or legal guardians who are unable to provide consent within 36 hours of birth will also be excluded.
Study Intervention/Methods Written parental informed consent will be obtained prenatally or within the first 36 hours of birth. Infants will be randomized to receive limited trophic feeds of 24 to 36 hours or extended trophic feeds for 72 hours prior to the advancement of enteral feeds. Infants will be fed parent's own milk (POM) with donor human milk as the alternative if POM is unavailable.
Primary Outcome Late-onset sepsis, defined as positive blood, urine, and/or cerebrospinal fluid (CSF) cultures in the presence of compatible clinical signs of sepsis, occurring after postnatal day 3 and before hospital discharge, and treated with antibiotics for 5 days or more.
Secondary Outcome(s) The trial will assess various secondary outcomes including length of hospital stay, all-cause in-hospital mortality, duration of IV fluids and central line utilization, necrotizing enterocolitis (Bell's stage IIa or higher), severe intraventricular hemorrhage (grade III or IV either unilaterally or bilaterally), bronchopulmonary dysplasia (oxygen requirement or positive pressure ventilation at 36 weeks corrected gestational age), or retinopathy of prematurity requiring intervention. Additionally, growth metrics throughout hospitalization will be evaluated using change in weight, length, and head circumference z-scores from birth to 36 weeks' corrected gestational age between infants in the limited and extended trophic feeding groups.
Conditions
- Sepsis
- Length of Stay
- Mortality
Interventions
- OTHER
-
Limited Trophic Feeds (1 day of trophic feeds)
Advancing enteral feeds after 1 day of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
- OTHER
-
Extended Trophic Feeds (3 days of trophics)
Advancing enteral feeds after 3 days of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day after 3 days of trophic feeds. Advancement will occur until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
Sponsors & Collaborators
-
University of Alabama at Birmingham
collaborator OTHER -
Baylor College of Medicine
collaborator OTHER -
University of South Florida
collaborator OTHER -
University of Oklahoma
collaborator OTHER -
St. Joseph's Medical Center
collaborator UNKNOWN - lead OTHER
Principal Investigators
-
Gregory C Valentine · University of Washington
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 0 Hours
- Max Age
- 36 Hours
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-07-03
- Primary Completion
- 2028-01-01
- Completion
- 2028-03-31
Countries
- United States
Study Locations
More Related Trials
-
Comparison of Early Versus Late Trophic Feeding
NCT07229885 ·Status: COMPLETED ·Phase: NA
-
Speed of Increasing Milk Feeds Trial
NCT01727609 ·Status: COMPLETED ·Phase: NA
-
Impact of Modified Feeding Protocol on Neonatal Outcomes
NCT06246032 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Early Total Enteral Feeding Versus Conventional Enteral Feeding in Stable Very Low Birth Weight Infants
NCT02187978 ·Status: COMPLETED ·Phase: NA
-
Early Versus Delayed Feeding in Preterm Growth-Restricted Infants
NCT03443297 ·Status: UNKNOWN ·Phase: NA
-
Targeted Nutrition for Moderate to Late Preterm Infants
NCT05515614 ·Status: COMPLETED ·Phase: NA
-
Exclusive Enteral Nutrition in Preterm Neonates
NCT04337710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluation of Preterm Infants Fed Post-Discharge Preterm Infant Formula
NCT03991949 ·Status: COMPLETED ·Phase: NA
-
Liquid Preterm Formula Versus Powdered Human Milk Fortifier in VLBW Infants
NCT00760942 ·Status: COMPLETED ·Phase: NA
-
Nutritional Status on Admission to Pediatric Intensive Care
NCT02293434 ·Status: COMPLETED
-
Feeding Study in VLBW Premature Infants
NCT05744193 ·Status: TERMINATED ·Phase: NA
-
Early Total Enteral Feeding Versus Convention Enteral Feeding in Preterm Infants 27-32 Weeks of Gestation
NCT06076460 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.
NCT03472170 ·Status: UNKNOWN ·Phase: NA
-
Clinical Tolerance of Numeta 13%
NCT01772927 ·Status: UNKNOWN
-
Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate
NCT01821989 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Re-feeding Gastric Residuals in Preterm Infants
NCT01420263 ·Status: COMPLETED ·Phase: NA
-
Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial
NCT03926390 ·Status: COMPLETED ·Phase: NA
-
Effects Of Not Measuring Gastric Residual Content On Feeding Tolerance In Premature Infants iNFANTS
NCT01965769 ·Status: COMPLETED ·Phase: NA
-
Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU
NCT04190875 ·Status: SUSPENDED
-
Dietary Protein in the Very-low-birth-weight Infant
NCT01208493 ·Status: TERMINATED ·Phase: NA
-
Lactulose Supplementation in Premature Infants
NCT00616876 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Early Limited Formula Use on Breastfeeding Outcomes
NCT00952328 ·Status: COMPLETED ·Phase: NA
-
Optimal Growth of Preterm Infants With Growth Restriction
NCT02999945 ·Status: WITHDRAWN ·Phase: NA
-
Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial
NCT01441427 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates
NCT07088302 ·Status: RECRUITING ·Phase: NA